



# Press Release

## **Munich Leukemia Laboratory MLL launches *Integrated Findings***

*Integrated Findings* as a new service in the diagnostics and treatment of leukemias

**With its newly introduced Integrated Findings, Münchner Leukämielabor GmbH (MLL) is defining an entirely new findings benchmark for leukemia diagnostics. The Integrated Findings provide doctors and their patients with a differentiated and equally comprehensible presentation of complex diagnostic and prognostic classification for leukemia diseases. The aim is to smoothen the path for individualized therapy.**

“The *Integrated Findings* give the attending physicians a comprehensive impression of available diagnostic findings. This facilitates the preparation of a therapy regime to ensure the best possible treatment outcome for affected patients,” says Torsten Haferlach, hematologist and one of the managing directors at MLL.

Produced by clinically and diagnostically experienced hematologists at MLL, the document integrates in one single assessment all the individual findings of cytomorphology, flow cytometry, cyto- and molecular genetics that are needed for diagnosis and prognosis. Moreover, the *Integrated Findings* provide additional interpretation, including designation of the diagnosis according to WHO classification (2017) and its assignment to obligatory prognostic scoring systems like the ELN-published IPSS-R etc., as well as recommended parameters for progress control. Integrated Findings are currently being prepared for patients with acute myeloid leukemia. Next in line will be a version for patients with myelodysplastic syndromes, and Integrated Findings for other entities are also in planning.

### **Pressekontakt**

MLL Münchner Leukämielabor GmbH, Presseabteilung, Kristina Kneis, Max-Lebsche-Platz 31, 81377 München  
Tel. +49 (0)89 99017 506, Mail: [presse@mll.com](mailto:presse@mll.com); [www.mll.com](http://www.mll.com)